Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients

Full item page Simple item page

• dc.contributor.author Martín-Varillas, José Luis
• dc.contributor.author Beltran-Catalan, Emma
• dc.contributor.author Blanco, Ricardo
• dc.date.accessioned 2023-05-09T06:13:25Z
• dc.date.available 2023-05-09T06:13:25Z
• dc.date.issued 2022
• dc.description.abstract Objectives: To evaluate effectiveness and safety of certolizumab pegol (CZP) in uveitis due to immune-mediated inflammatory diseases (IMID). Methods: Multicentre study of CZP-treated patients with IMID uveitis refractory to conventional immunosuppressant. Effectiveness was assessed through the following ocular parameters: best-corrected visual acuity, anterior chamber cells, vitritis, macular thickness and retinal vasculitis. These variables were compared between the baseline, and first week, first, third, sixth months, first and second year. Results: We studied 80 (33 men/47 women) patients (111 affected eyes) with a mean age of 41.6±11.7 years. The IMID included were: spondyloarthritis (n=43), Behçet's disease (n=10), psoriatic arthritis (n=8), Crohn's disease (n=4), sarcoidosis (n=2), juvenile idiopathic arthritis (n=1), reactive arthritis (n=1), rheumatoid arthritis (n=1), relapsing polychondritis (n=1), CONCLUSIONS: CZP seems to be effective and safe in uveitis related to different IMID, even in patients refractory to previous biological drugs.
• dc.format.mimetype application/pdf
• dc.identifier.citation Martín-Varillas JL, Sanchez-Bilbao L, Calvo-Río V, Adán A, Hernanz I, Gallego-Flores A, et al. Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients. RMD Open. 2022 Dec;8(2):e002693. DOI: 10.1136/rmdopen-2022-002693
• dc.identifier.doi http://dx.doi.org/10.1136/rmdopen-2022-002693
• dc.identifier.issn 2056-5933
• dc.identifier.uri http://hdl.handle.net/10230/56719
• dc.language.iso eng
• dc.publisher BMJ Publishing Group
• dc.relation.ispartof RMD Open. 2022 Dec;8(2):e002693
• dc.rights © Author(s) (or their employer(s)) 2022. Re-use permitted under CC BY-NC. No commercial re-use. See rights and permissions. Published by BMJ. This is an open access article distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited, appropriate credit is given, any changes made indicated, and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/.
• dc.rights.accessRights info:eu-repo/semantics/openAccess
• dc.rights.uri http://creativecommons.org/licenses/by-nc/4.0/
• dc.subject.keyword Autoimmune diseases
• dc.subject.keyword Biological therapy
• dc.subject.keyword Certolizumab pegol
• dc.subject.keyword Systemic vasculitis
• dc.title Long-term follow-up of certolizumab pegol in uveitis due to immune-mediated inflammatory diseases: multicentre study of 80 patients
• dc.type info:eu-repo/semantics/article
• dc.type.version info:eu-repo/semantics/publishedVersion